Feb 6th, 2007, 17:25
|
只看该作者 #287 | |
|
Senior Member
  
注册日期: Sep 2006
帖子: 699
积分:2
精华:2
声望: 37769
  |
CSCO 出ER了, 盘后涨. After Hours Last: $ 28.50 After Hours High: $ 28.84 After Hours Volume: 101,396,692 After Hours Low: $ 27.12 After Hours Time (ET) After Hours Price After Hours Share Volume 17:09 $ 28.48 200 17:09 $ 28.48 1,000 17:09 $ 28.47 200 17:09 $ 28.47 9,800 17:09 $ 28.47 2,000 17:09 $ 28.46 2,256 17:09 $ 28.47 500 17:09 $ 28.49 引用:
|
|
|
|
|
Feb 7th, 2007, 19:44
|
只看该作者 #293 | |
|
Senior Member
注册日期: Sep 2006
帖子: 699
积分:2
精华:2
声望: 37769
|
我有股票和CALL OPTION. 关注ing. Level 3 Shares Up Ahead of 4Q Report Wednesday February 7, 3:41 pm ET Level 3 Communications Rises Ahead of 4Q Earnings Report; Bear Stearns Anticipates Strength NEW YORK (AP) -- Shares of Internet connection provider Level 3 Communications Inc. rose Wednesday after a Bear Stearns analyst said he expects a strong fourth-quarter report from the company. Shares added 34 cents, or 5.4 percent, to $6.69 in afternoon trading on the Nasdaq. The stock has traded in a 52-week range of $3.22 to $6.80, and is up 81 percent in the same period. Michael McCormack lifted his target price on the company to $8.50 from $7.75 and reiterated an "Outperform" rating ahead of the quarterly report. The analyst said he expects the report to include strong organic revenue growth due to significant volume increases and stabilizing pricing. In addition, results should be boosted by improved margins, which could be partially offset by integration expenses, he added. McCormack expects robust sales trends to continue supporting shares in 2007. Level 3 reports its earnings Thursday before the morning bell. 引用:
|
|
|
|
|
|
Feb 7th, 2007, 21:36
|
只看该作者 #294 | |
|
Senior Member
 
注册日期: Nov 2004
帖子: 1,217
积分:2
精华:2
声望: 69630
|
CSCO
引用:
今天平仓的话，按比较合理的平仓价格，$3.7卖出 1 FEB 25 Call，$1.2买回 2个FEB 27.5 Call，利润为0.6，也还不错。重要的是卖掉的2个 FEB 27.5 Call对冲了股价下跌的风险。 注：以上为假想情况，并非实际操作。 |
|
|
|
|
|
Feb 8th, 2007, 08:57
|
只看该作者 #295 | |
|
Senior Member
注册日期: Sep 2006
帖子: 699
积分:2
精华:2
声望: 37769
|
Level 3 Reports Fourth Quarter and Full Year 2006 Results Thursday February 8, 7:30 am ET Continued Strong Core Communications Services Organic Growth Company Expects Significant Communications Revenue and Consolidated Adjusted OIBDA Growth in 2007 Financial and Business Highlights * Consolidated Revenue of $846 million * Net Loss of $237 million, or $0.20 per share * Consolidated Adjusted OIBDA of $189 million * Consolidated Free Cash Flow of negative $29 million * Organic core communications services revenue growth of 8 percent quarter over quarter and 25 percent in 2006 BROOMFIELD, Colo., Feb. 8 /PRNewswire-FirstCall/ -- Level 3 Communications, Inc. (Nasdaq: LVLT - News) reported consolidated revenue of $846 million for the fourth quarter 2006, compared to consolidated revenue of $875 million for the third quarter 2006. For the full year 2006, consolidated revenue was $3.38 billion, compared to $1.72 billion in 2005. The net loss for the fourth quarter 2006 was $237 million, or $0.20 per share, compared to a net loss of $138 million, or $0.12 per share, for the previous quarter. Included in the net loss for the fourth quarter was a $54 million loss on the extinguishment of debt, or $0.05 per share. Included in the net loss for the third quarter was a gain of $33 million associated with the sale of Software Spectrum, or $0.03 per share. "Level 3 had a strong fourth quarter," said James Q. Crowe, CEO of Level 3. "Organic core revenue growth was 8 percent during the quarter and 25 percent annualized for the full year 2006, which excludes the benefits of acquisition and termination revenue. This growth is a result of ongoing customer demand and a healthy industry operating environment. We expect these positive trends to continue in 2007." Consolidated Adjusted OIBDA(1) defined as Adjusted Operating Income Before Depreciation and Amortization was $189 million in the fourth quarter 2006, compared to $176 million for the third quarter 2006. Consolidated Adjusted OIBDA for 2006 was $682 million, compared to $471 million in 2005. Fourth Quarter 2006 and Full Year 2006 and 2005 Financial Results Consolidated Fourth Consoli- Full Year Consoli- Metric Fourth Quarter 2006 dated 2006 dated Revenue Quarter 2006 Projec- Full Year Projec- Full Year ($ in millions) Results tions(1) 2006 Results tions(1) Results Core Communi- cations Services(2) $619 $595 - $605 $1,973 $1,950-$1,960 $962 Other Communi- cations Services $95 $90 - $95 $445 $440 - $445 $658 SBC Contract Services $116 $100 - $130 $893 $875 - $905 $25 Total Communications Revenue $830 $785 - $830 $3,311 $3,265-$3,310 $1,645 Other Revenue $16 $67 $74 Total Consolidated Revenue $846 $3,378 $1,719 Consolidated Adjusted OIBDA (3) (4) $189 $180 - $200 $682 $670 - $690 $471 Capital Expenditures $141 $392 $390 - $410 $300 Unlevered Cash Flow (4) $65 $324 $(2) Free Cash Flow (4) $(29) $(171) $(418) Communications Gross Margin (4) 63% 56% 72% Communications Adjusted OIBDA Margin (4) 22% ~23% 20% ~21% 28% (1) Projections issued October 24, 2006 (2) Includes termination revenue of $8 million in the fourth quarter 2006, $11 million for the full year 2006, and $133 million for the full year 2005 (3) Consolidated Adjusted OIBDA excludes $32 million in non-cash compensation expense for the fourth quarter 2006, $84 million for the full year 2006, and $51 million for the full year 2005. Consolidated Adjusted OIBDA also excludes $8 million of non-cash impairment charges for 2006 and $9 million for 2005 (4) See schedule of non-GAAP metrics for definition and reconciliation to GAAP measures Communications Business Revenue Communications revenue for the fourth quarter 2006 was $830 million, versus $858 million for the previous quarter. Communications revenue decreased as a result of declines in Other Communications Services revenue and SBC Contract Services. The company recognized $8 million in termination revenue during the fourth quarter 2006 and less than $1 million in termination revenue during the third quarter 2006. Communications revenue for 2006 was $3.31 billion, compared to $1.6 billion in 2005. 引用:
|
|
|
|
|
|
Feb 8th, 2007, 23:28
|
只看该作者 #296 |
|
Senior Member
注册日期: Sep 2006
帖子: 699
积分:2
精华:2
声望: 37769
|
PMED 学习贴: Paradigm Medical Industries, Inc. PMED - Paradigm Medical Industries, Inc. engages in the design, development, manufacture, and sale of diagnostic and surgical eye care products. The company?s products include P55 Pachymetric analyzer, P37 A/B Scan Ocular ultrasound diagnostic product, P40 and UBM ultrasound biomicroscope, P45 and P60 UBM ultrasound biomicroscope workstation plus, BFA ocular Blood Flow Analyzer and disposables, topography system CT 200 corneal, and LD 400 and TKS 5000 autoperimetry system General The following Management's Discussion and Analysis of Financial Condition and Results of Operations, contains forward-looking statements, which involve risks and uncertainty. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors discussed in this section. The Company's fiscal year is from January 1 through December 31. The Company is engaged in the design, development, manufacture and sale of high technology diagnostic and surgical eye care products. Given the "going concern" status of the Company, management has focused efforts on those products and activities that will, in its opinion, achieve the most resource efficient short-term cash flow. As seen in the results for the three months ended September 30, 2006, diagnostic products have been the major focus and the Photon(TM) and other extensive research and development projects have been put on hold pending future evaluation when the Company's financial position improves. The Company does not focus on a specific diagnostic product or products but, instead, on the entire diagnostic product group. 此帖于 Feb 8th, 2007 23:52 被 chinasmile1 编辑。 |
|
|
|
|
Feb 8th, 2007, 23:29
|
只看该作者 #297 |
|
Senior Member
注册日期: Sep 2006
帖子: 699
积分:2
精华:2
声望: 37769
|
Results of Operations Three Months Ended September 30, 2006, Compared to Three Months Ended September 30, 2005 Net sales for the three months ended September 30, 2006 decreased by $132,000, or 24%, to $418,000 as compared to $550,000 for the same period of 2005. This reduction in sales was primarily due to reduced sales of the P40, P45 and P60 UBM Ultrasound Biomicroscopes and the P37 A/B Scan Ocular Ultrasound Diagnostics. For the three months ended September 30, 2006, sales from the Company's diagnostic products totaled $348,000, or 83% of total revenues, compared to $600,000 for the same period of 2005. The remaining 17% of sales, or $70,000 during the three months ended September 30, 2006 was from parts, disposables, and service revenue. Sales of the P40, P45 and P60 UBM Ultrasound Biomicroscopes decreased to $40,000 during the three months ended September 30, 2006, or 10% of total quarterly revenues for the period, compared to $419,000, or 76% of total revenues, for the same period last year. Sales of the Blood Flow Analyzer(TM) increased by $28,000 to $42,000, or 10% of total revenues, for the nine months ended September 30, 2006, compared to net sales of $14,000, or 3% of total revenues, during the same period in 2005. Sales from the P37 A/B Scan Ocular Ultrasound Diagnostic decreased to $20,000, or 5% of total revenues, for the three month period ended September 30, 2006, down compared to $48,000, or 9% of total revenues, for the same period last year. Combined sales of the LD 400 and TKS 5000 autoperimeters and the CT 200 Corneal Topographer were $175,000, or 42% of the total revenues, for the three months ended September 30, 2006, compared to $119,000, or 22% of total revenues, for the same period of 2005. Sales have been lower during the three months ended September 30, 2006 for the Company due to a variety of reasons. Sales of the P40, P45 and P60 UBM Ultrasound Biomicroscope decreased primarily as a result of ongoing software development and hardware configuration problems with the new P60, which received FDA 510(k) premarket approval on May 26, 2005 that allowed the device to be sold in the United States. The hardware configuration problems have since been resolved and the Company continues to work on resolving the software development problems. The Company anticipates reversing the downward trend in sales through additional efforts by the Company to gain more widespread support for the P60 through increased clinical awareness, product development and improved marketing plans. Sales of surgical products are at a standstill pending FDA approval of the Photon(TM) laser system. In the three month period ended September 30, 2006, the Company realized no sales in the surgical line consisting of the Precissionist Thirty Thousand(TM) and the Photon(TM) laser system. There were also no sales in the surgical line for the comparable period of 2005. For the three months ended September 30, 2006, gross profit decreased slightly by 5% to 51% of total revenues, compared to 56% of total revenues for the same period in 2005. Marketing and selling expenses decreased by $20,000, or 14%, to $123,000, for the three months ended September 30, 2006, from $143,000 for the comparable period in 2005. The reduction was primarily due to a reduced number of sales representatives and lower travel related and associated sales expenses. General and administrative expenses decreased by $54,000, or 17%, to $258,000 for the three months ended September 30, 2006, from $312,000 for the comparable period in 2005. The decrease in general and administrative expenses was primarily due to a reduction in management salaries and in the number of employees, and enhanced operating efficiencies. In addition, during the first quarter of 2005, the Company issued 515,206 shares of common stock to two shareholders that had purchased shares of the Company's Series G convertible preferred stock in a private offering. Under the terms of the private offering, the Company was required to file a registration statement with the Securities and Exchange Commission for the purpose of registering the common shares issuable to the Series G preferred stockholders upon conversion of their Series G preferred shares and exercise of their warrants. The shares were issued as a penalty for the Company not having a registration statement declared effective within 120 days of the initial closing of the private offering. Research, development and service expenses decreased by $81,000, or 38%, to $130,000 for the three months ended September 30, 2006, compared to $211,000 in the same period of 2005. Most of the reduction was due to the reduced costs of product development for the three months ended September 30, 2006, as compared to the increased costs of development and compliance with regulatory requirements in releasing the new P60 UBM that were incurred during the same period in 2005. Due to our ongoing cash flow difficulties, most of the Company's vendors and suppliers were contacted during 2004 and 2005 with attempts to negotiate reduced payments and settlement of outstanding accounts payable. While some vendors refused to negotiate and demanded payment in full, some vendors were willing to settle for a reduced amount. The accounts payable forgiven by vendors and suppliers resulted in a gain of $12,000 and $206,000 during the years ended December 31, 2005 and 2004, respectively. In 2006 the Company is continuing its negotiations with some vendors and suppliers. Nine Months Ended September 30, 2006, Compared to Nine Months Ended September 30, 2005 Net sales for the nine months ended September 30, 2006 decreased by $363,000, or 18%, to $1,600,000 as compared to $1,963,000 for the same period of 2005. This reduction in sales was primarily due to reduced sales of the P40, P45 and P60 UBM Ultrasound Biomicroscopes and the P37 A/B Scan Ocular Ultrasound Diagnostics. For the nine months ended September 30, 2006, sales from the Company's diagnostic products totaled $1,374,000, or 86% of total revenues, compared to $1,771,000, or 90% of total revenues for the same period of 2005. The remaining 14% of sales, or $226,000 during the nine months ended September 30, 2006 was from parts, disposables, and service revenue. Sales of the P40, P45 and P60 UBM Ultrasound Biomicroscopes decreased to $293,000 during the nine months ended September 30, 2006, or 18% of total quarterly revenues for the period, compared to $1,096,000 or 56% of total revenues, for the same period last year. Sales of the Blood Flow Analyzer(TM) increased by $52,000 to $128,000, or 8% of total revenues, for the nine months ended September 30, 2006, compared to net sales of $76,000, or 4% of total revenues, during the same period in 2005. Sales from the P37 A/B Scan Ocular Ultrasound Diagnostic increased to $140,000, or 9% of total revenues, for the nine month period ended September 30, 2006, down compared to $128,000, or 7% of total revenues, for the same period last year. Combined sales of the LD 400 and TKS 5000 autoperimeters and the CT 200 Corneal Topographer were $715,000, or 45% of the total revenues, for the nine months ended September 30, 2006, compared to $471,000, or 24% of total revenues, for the same period of 2005. Sales have been lower during the nine months ended September 30, 2006 for the Company due to a variety of reasons. Sales of the P40, P45 and P60 UBM Ultrasound Biomicroscope decreased primarily as a result of ongoing software development and hardware configuration problems with the new P60, which received FDA 510(k) premarket approval on May 26, 2005 that allowed the device to be sold in the United States. The hardware configuration problems have since been resolved and the Company continues to work on resolving the software development problems. The Company anticipates reversing the downward trend in sales through additional efforts by the Company to gain more widespread support for the P60 through increased clinical awareness, product development and improved marketing plans. Sales of surgical products are at a standstill pending FDA approval of the Photon(TM) laser system. In the nine month period ended September 30, 2006, the Company realized no sales in the surgical line consisting of the Precissionist Thirty Thousand(TM) and the Photon(TM) laser system. There were also no sales in the surgical line for the comparable period of 2005. For the nine months ended September 30, 2006, gross profit decreased slightly by 5% to 47% of total revenues, compared to 52% of total revenues for the same period in 2005. Marketing and selling expenses decreased by $202,000, or 40%, to $307,000, for the nine months ended September 30, 2006, from $509,000 for the comparable period in 2005. The reduction was due primarily to a reduced number of sales representatives and lower travel related and associated sales expenses. General and administrative expenses decreased by $192,000, or 20%, to $772,000 for the nine months ended September 30, 2006, from $964,000 for the comparable period in 2005. The decrease in general and administrative expenses was primarily due to a reduction in management salaries and in the number of employees, and enhanced operating efficiencies. In addition, during the first quarter of 2005, the Company issued 515,206 shares of common stock to two shareholders that had purchased shares of the Company's Series G convertible preferred stock in a private offering. Under the terms of the private offering, the Company was required to file a registration statement with the Securities and Exchange Commission for the purpose of registering the common shares issuable to the Series G preferred stockholders upon conversion of their Series G preferred shares and exercise of their warrants. The shares were issued as a penalty for the Company not having a registration statement declared effective within 120 days of the initial closing of the private offering. Also during 2005, the Company collected $1,000 in receivables that were previously allowed in the allowance for doubtful accounts. During 2005, the Company increased allowance for doubtful accounts by $100,000. Research, development and service expenses decreased by $81,000, or 38%, to $130,000 for the three months ended September 30, 2006, compared to $211,000 in the same period of 2005. Most of the reduction was due to the reduced costs of product development for the nine months ended September 30, 2006, as compared to the increased costs of development and compliance with regulatory requirements in releasing the new P60 UBM that were incurred during the same period in 2005. Due to our ongoing cash flow difficulties, most of the Company's vendors and suppliers were contacted during 2004 and 2005 with attempts to negotiate reduced payments and settlement of outstanding accounts payable. While some vendors refused to negotiate and demanded payment in full, some vendors were willing to settle for a reduced amount. The accounts payable forgiven by vendors and suppliers resulted in a gain of $12,000 and $206,000 during the years ended December 31, 2005 and 2004, respectively. In 2006 the Company is continuing its negotiations with some vendors and suppliers. Liquidity and Capital Resources The Company used $766,000 in cash in operating activities for the nine months ended September 30, 2006, compared to $2,493,000 for the nine months ended September 30, 2005. The decrease in cash used for operating activities for the nine months ended September 30, 2006 was primarily attributable to the Company's net loss and decreases in accounts payable and accrued liabilities and an increase in inventory, specifically for the P60 UBM. The Company used $19,000 in investing activities for the nine months ended September 30, 2006, compared to $-0- for the nine months ended September 30, 2005. Net cash received in financing activities was $986,000 for the nine months ended September 30, 2006, versus cash provided from financing activities of $2,611,000 in the same period in 2005. The Company had working capital of $360,000 as of September 30, 2006, compared to working capital of $1,221,000 as of September 30, 2005. In January 2005, the Company sold 2,000,000 shares of its common stock to an accredited investor for $150,000 in cash. In the past, the Company has relied heavily upon sales of the Company's common and preferred stock to fund operations. There can be no assurance that such equity funding will be available on terms acceptable to the Company in the future. As of September 30, 2006, the Company had net operating loss carry-forwards (NOLs) of approximately $53 million. These loss carry-forwards are available to offset future taxable income, if any, and have begun to expire in 2001 and extend for twenty years. The Company's ability to use net operating loss carryforwards (NOLs) to offset future income is dependant upon certain limitations as a result of the pooling transaction with Vismed and the tax laws in effect at the time of the NOLs can be utilized. The Tax Reform Act of 1986 significantly limits the annual amount that can be utilized for certain of these carryforwards as a result of change of ownership. As of September 30, 2006, the Company had accounts payable of $336,000, a significant portion of which was over 90 days past due, compared to accounts payable of $530,000 as of September 30, 2005. The Company has contacted many of the vendors or companies that have significant amounts of payables past due in an effort to delay payment, renegotiate a reduced settlement payment, or establish a longer-term payment plan. While some companies have been willing to renegotiate the outstanding amounts, others have demanded payment in full. Under certain conditions, including but not limited to judgments rendered against the Company in a court of law, a group of creditors could force the Company into bankruptcy due to its inability to pay the liabilities arising out of such judgments at that time. In addition to the accounts payable noted above, the Company also has non-cancelable capital lease obligations and operating lease obligations that required the payment of approximately $194,000 in 2005, and $14,000 in 2006. The Company has taken numerous steps to reduce costs and increase operating efficiencies. These steps consist of the following: 1. The Company closed its San Diego facility. In so doing, numerous manufacturing, accounting and management responsibilities were consolidated. In addition, such closure resulted in significant headcount reductions as well as savings in rent and other overhead costs. 2. The Company has significantly reduced the use of consultants, which has resulted in a large decrease to these expenses. 3. The Company has reduced its direct sales force to three representatives, which has resulted in less payroll, travel and other selling expenses. Because the Company has significantly fewer sales representatives, its ability to generate sales has been reduced. The Company has taken measures to reduce the amount of uncollectible accounts receivable such as more thorough and stringent credit approval, improved training and instruction by sales personnel, and frequent direct communication with the customer subsequent to delivery of the system. The allowance for doubtful accounts was 25% of total outstanding receivables as of September 30, 2006 and 20% as of December 31, 2005 compared to 2% of total outstanding receivables as of September 30, 2005. The allowance for doubtful accounts decreased from $100,000 at December 31, 2005 to $95,000 at September 30, 2006. The Company intends to continue its efforts to reduce the allowance for doubtful accounts as a percentage of accounts receivable. The Company has ongoing efforts to collect a significant portion of the sales price in advance of the sale or in a timely manner after delivery. During the nine months ended September 30, 2006, the Company added a net of $-0- to the allowance for doubtful accounts. The Company believes that by requiring a large portion of payment prior to shipment, it has greatly improved the collectibility of its receivables. The Company carried an allowance for obsolete or estimated non-recoverable inventory of $1,333,000 at September 30, 2006 and $1,371,000 at September 30, 2005, or 60% and 51% of total inventory, respectively. The Company's means of expansion and development of product has been largely from acquisition of businesses, product lines, existing inventory, and the rights to specific products. Through such acquisitions, the Company has acquired substantial inventory, some of which the eventual use and recoverability was uncertain. In addition, the Company has a significant amount of inventory relating to the Photon(TM) laser system, which does not yet have FDA approval in order to sell the product domestically. Therefore, the allowance for inventory was established to reserve for these potential eventualities. On a quarterly basis, the Company attempts to identify inventory items that have shown relatively no movement or very slow movement. Generally, if an item has shown little or no movement for over a year, it is determined not to be recoverable and a reserve is established for that item. In addition, if the Company identifies products that have become obsolete due to product upgrades or enhancements, a reserve is established for such products. The Company intends to make efforts to sell these items at significantly discounted prices. If items are sold, the cash received would be recorded as revenue, but there would be no cost of sales on such items due to the reserve that has been recorded. At the time of sale, the inventory would be reduced for the item sold and the corresponding inventory reserve would also be reduced. At this time, the Company's Photon(TM) Laser Ocular Surgery Workstation requires regulatory FDA approval in order to be sold in the United States. Any possible future efforts to complete the clinical trials on the Photon(TM) in order to file for FDA approval would depend on the Company obtaining adequate funding. The Company estimates that the funds needed to complete the clinical trials in order to obtain the necessary regulatory approval on the Photon(TM) to be approximately $225,000. Effect of Inflation and Foreign Currency Exchange The Company has not realized a reduction in the selling price of its products as a result of domestic inflation. Nor has it experienced unfavorable profit reductions due to currency exchange fluctuations or inflation with its foreign customers. All sales transactions to date have been denominated in U.S. dollars. 此帖于 Feb 8th, 2007 23:58 被 chinasmile1 编辑。 |
|
|
|
|
Feb 8th, 2007, 23:36
|
只看该作者 #299 |
|
Senior Member
注册日期: Sep 2006
帖子: 699
积分:2
精华:2
声望: 37769
|
Healthcare next big thing for China's VC (AFP) Updated: 2007-01-29 11:37 Partial article: http://www.chinadaily.com.cn/china/2007-... Four years ago, Joe Zhou and his partners at Softbank Asia Infrastructure Fund (SAIF) made an investment of $40 million into Shanghai-based online game operator Shanda Interactive Entertainment Co Ltd. The investment was believed to be highly risky, as the prospect of online games was uncertain in China and Shanda was in legal trouble with its South Korean partner. However, the venture capital (VC) firm turned out to be a successful pioneer in leading an investment wave into online game companies with over 10 times in returns in less than two years. Since then, other venture capital firms have closely watched the moves of Zhou and his partners. Now Zhou, a venture partner with SAIF since 2001, is trying to lead the venture capital trend again. This time, he's looking to the healthcare industry. "We manage a fund of $1 billion, and the first investment in the healthcare industry happened last year; this move is typical among venture capital firms," says the 46-year-old Zhou, who holds a masters in electrical engineering from the New Jersey Institute of Technology. According to the Beijing-based VC industry consultancy Zero2ipo Co Ltd, there was $4 billion in venture capital funds in China in 2006, and $1.78 billion have been invested. Of those investments, less than 60 percent went to the traditionally favorite information technology sector, down from 66 percent in 2005. On one hand, say experts, there is plenty of money available. On the other, too much concentration on the Internet drives up the valuation of a single deal. Now, when VC companies search for new targets, firms involved with healthcare often attract their attention. Milestone for the sector On September 26, Shenzhen-based Mindray Medical International Ltd, a minor competitor of GE in medical monitoring equipment and ultrasound scanning equipment, listed its stocks on the New York Stock Exchange (NYSE) and raised $311 million from the public offering. "This is a milestone of China's healthcare industry, but it is equally important to the global healthcare industry, as it is the largest IPO in the business in the past two years," says Ge Yang, a representative of NYSE in China. According to Zero2ipo, four Chinese healthcare companies made overseas public offerings last year and nine mergers and acquisitions took place, showing increasing interest from investors. The prospect of China's healthcare industry is also encouraging to investors. The US pharmaceutical consulting firm IMS Health says in its global industrial forecast that China's pharmaceutical industry will grow at 15-16 percent to $1.5-1.6 billion in 2007, compared against a global average growth of 5-6 percent. Jiang Feng, president of the China Medical Equipment Industry Association, says that the proportion of the whole healthcare industry, including hospitals, medicine and equipment, only accounts for about 3 percent of gross domestic production in China, while the proportion in developed countries like the United States and Japan is around 10 percent. The issue of intellectual property rights (IPR) remains a big concern for investors. But the IPR protection situation is improving, experts say, as the Chinese government recognizes its importance in building a country not dependent on low-end manufacturing. |
|
|
|
|
Feb 8th, 2007, 23:40
|
只看该作者 #300 | |
|
Senior Member
注册日期: Sep 2006
帖子: 699
积分:2
精华:2
声望: 37769
|
RUMOR: PMED's Photon(TM) laser system is next for FDA APPROVAL. PMED Sales of surgical products are at a standstill pending FDA approval of the Photon(TM) laser system. In the three month period ended September 30, 2006, the Company realized no sales in the surgical line consisting of the Precissionist Thirty Thousand(TM) and the Photon(TM) laser system 引用:
|
|
|
|
|
